News & Events

ONDRI Aim 4’s deep dive into the correlation of history of neurological or psychiatric conditions in Ontario was recently highlighted in key research and academic publications.

ONDRI in partnership with the Ontario Brain Institute (OBI) has released de-identified baseline data from the deeply phenotyped ONDRI Foundational Study (2013-2018).

Congratulations to ONDRI co-lead, Dr. Mario Masellis, for coordinating an international study that has received €1,086,421 in funding through the Joint Program in Neurodegenerative Disease (JPND) call entitled ‘Linking Pre-Diagnosis Disturbances of Physiological Systems to Neurodegenerative Diseases.’

Congratulations to Dr. Mario Masellis and all the contributors to this important report published by Alzheimer’s Disease International.

Queen’s University researcher and ONDRI co-lead Doug Munoz, PhD has been elected to the Canadian Academy of Health Sciences (CAHS) Fellowship, one of Canada’s premier academic honours.

A medication called aducanumab is in the early stages of review for potential approval in Canada. Aducanumab was recently approved, with conditions, in the U.S., where it can now be prescribed for mild Alzheimer’s disease. ONDRI joined with other expert organizations working in Alzheimer’s and dementia research to devise a consensus statement on Aducanumab.

The 2021 AAIC conference took place on July 26-30, 2021, in Denver, Colorado and concurrently as a virtual event. This annual conference is an opportunity to showcase important research in Alzheimer’s disease and dementia from around the world.

Dr. Richard Swartz, ONDRI co-lead, will be presenting his research on the complex impacts of COVID-19 on stroke risk, care and outcomes

ONDRI researchers have co-authored a paper highlighting promising new potential Parkinson’s Disease (PD) biomarkers (or early indicators of disease).

Neurodegenerative disease research innovations through ONDRI@Home, based in Waterloo, Ontario, were featured in a news release.